Fox Run Management L.L.C. Grows Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Fox Run Management L.L.C. boosted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 67.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 68,040 shares of the biotechnology company’s stock after buying an additional 27,406 shares during the period. Fox Run Management L.L.C.’s holdings in BioCryst Pharmaceuticals were worth $512,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of BCRX. Venturi Wealth Management LLC bought a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $46,000. R Squared Ltd purchased a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter worth about $48,000. KBC Group NV boosted its stake in BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 4,537 shares during the last quarter. Raymond James Financial Inc. purchased a new position in BioCryst Pharmaceuticals during the 4th quarter valued at approximately $80,000. Finally, Quantinno Capital Management LP bought a new stake in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $82,000. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Trading Up 0.2 %

BCRX stock opened at $8.07 on Wednesday. The stock has a market cap of $1.69 billion, a PE ratio of -13.23 and a beta of 1.85. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $9.50. The company has a 50-day moving average price of $8.14 and a 200 day moving average price of $7.82.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $126.64 million. During the same quarter last year, the company posted $0.28 earnings per share. The business’s revenue was up 40.8% on a year-over-year basis. Sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on BCRX shares. Needham & Company LLC increased their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. JMP Securities reiterated a “market outperform” rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Evercore ISI boosted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price target for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $11.00 price objective (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.